Preventing Treatment-Induced Peripheral Neuropathy in Cancer Care

Abstract

Treatment-induced peripheral neuropathy (TIPN) is a common, often dose-limiting complication of several essential cancer therapies, notably platinum-based agents, taxanes, vinca alkaloids, and proteasome inhibitors. TIPN can profoundly impact patients quality of life and functional status, and may necessitate reduction or discontinuation of life-saving oncologic therapy. This review synthesizes recent evidence regarding the epidemiology, mechanisms, risk factors, clinical presentation, diagnosis, and evidence-based preventive and management strategies for TIPN. Recent advances in neuroprotective interventions, guideline recommendations, and practical strategies for risk mitigation are discussed, with emphasis on the integration of current research findings into clinical oncology practice.

Introduction

Peripheral neuropathy is a frequent and often debilitating adverse effect of modern cancer therapy, particularly with neurotoxic agents such as platinum compounds, taxanes, and vinca alkaloids. The onset of TIPN presents a significant clinical challenge, as it may compromise optimal oncologic dosing and negatively affect survivorship outcomes. Early identification, risk stratification, and implementation of preventive strategies are essential to minimize the burden of TIPN while maintaining therapeutic intensity. This article aims to provide clinicians and oncology professionals with an up-to-date, comprehensive review of TIPN and its prevention, grounded in recent clinical and translational research.

Epidemiology / Disease Burden

TIPN occurs in approximately 30–68% of patients receiving neurotoxic chemotherapies, with prevalence varying based on agent, dosing schedule, and cumulative exposure. Taxane-induced neuropathy affects 50–70% of patients, while platinum compounds such as oxaliplatin and cisplatin are associated with rates of 30–50%. Proteasome inhibitors, particularly bortezomib, also present a substantial risk, with up to 40% of treated patients developing neuropathy. TIPN is a leading cause of dose modification or discontinuation, directly impacting cancer outcomes. Chronic neuropathy persists in a significant subset of survivors, often resulting in long-term disability, impaired mobility, and reduced quality of life.

Pathophysiology

The pathogenesis of TIPN involves direct and indirect mechanisms, varying between drug classes. Platinum agents induce DNA crosslinking and mitochondrial dysfunction in dorsal root ganglia (DRG) neurons, leading to sensory axonopathy. Taxanes destabilize microtubules, disrupting axonal transport and causing both sensory and motor fiber damage. Vinca alkaloids impair microtubule assembly, affecting both peripheral nerves and Schwann cells, while proteasome inhibitors induce endoplasmic reticulum stress and mitochondrial toxicity. Inflammation, oxidative stress, and impaired axonal regeneration contribute further to neuronal injury. Genetic polymorphisms in drug metabolizing enzymes and neuronal repair pathways also modulate individual susceptibility to TIPN.

Risk Factors

Several patient- and treatment-related factors increase the likelihood of TIPN. Older age, pre-existing peripheral neuropathy (e.g., diabetic neuropathy), cumulative chemotherapy dose, rapid infusion rates, and combination regimens are established risk factors. Additional contributors include renal or hepatic dysfunction, pharmacogenomic variations (e.g., CYP2C8, GSTP1, ABCB1 genotypes), and co-administration of other neurotoxic agents. Identification and stratification of high-risk patients is critical for targeted prophylactic strategies.

Clinical Features

TIPN primarily manifests as symmetric sensory neuropathy with a stocking-glove distribution. Symptoms include paresthesias, numbness, burning pain, and proprioceptive deficits, often progressing with cumulative exposure. Severe cases may present with motor weakness, gait disturbance, or autonomic dysfunction. Onset may be acute, particularly with oxaliplatin, or insidious and progressive. TIPN can lead to functional impairment, falls, and decreased ability to perform activities of daily living, making early recognition vital for intervention.

Diagnosis

Diagnosis of TIPN is clinical, based on symptom assessment, neurologic examination, and temporal association with chemotherapy exposure. Standardized tools such as the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Total Neuropathy Score (TNS) are valuable for grading severity and monitoring progression. Electrophysiological studies (nerve conduction studies, electromyography) may help differentiate TIPN from other neuropathies and assess severity. Baseline and serial assessments are recommended for early detection and management.

Treatment & Management

Management of TIPN centers on prevention, symptom control, and functional rehabilitation. Dose modification, temporary discontinuation, or switching to less neurotoxic regimens are often necessary when significant neuropathy develops. Symptomatic treatments include duloxetine, which has demonstrated efficacy in reducing neuropathic pain, as well as tricyclic antidepressants, gabapentinoids, and topical agents. Physical and occupational therapy play a crucial role in maintaining mobility and function. Patient education and regular monitoring are essential components of comprehensive care.

Recent Advances / Emerging Therapies

Recent research has focused on neuroprotective agents and novel interventions to prevent TIPN. Several randomized controlled trials have investigated agents such as glutathione, calcium and magnesium infusions, acetyl-L-carnitine, and vitamin E, with mixed results. Duloxetine remains the only agent with clear evidence for symptomatic relief, while other agents such as omega-3 fatty acids, minocycline, and erythropoietin are under evaluation. Technological advances, including wearable sensors and digital monitoring, may aid in early detection and individualized risk assessment. Ongoing investigations into pharmacogenomics and biomarkers hold promise for personalizing TIPN prevention strategies.

Guideline Recommendations

Current clinical guidelines from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommend baseline and periodic assessment of neuropathic symptoms in patients receiving neurotoxic chemotherapy. Dose reduction or discontinuation is advised for moderate to severe TIPN. Pharmacologic prevention is not routinely recommended due to insufficient evidence for most agents, but duloxetine may be offered for established painful neuropathy. Multidisciplinary care, incorporating oncologists, neurologists, pharmacists, and rehabilitation specialists, is emphasized for optimal management. Patient education and shared decision-making are critical to balance oncologic efficacy with quality of life.

Conclusion

Treatment-induced peripheral neuropathy remains a significant challenge in cancer care, with substantial implications for survivorship and quality of life. While prevention strategies remain limited, a combination of risk stratification, vigilant monitoring, dose adjustments, and supportive care form the cornerstone of TIPN management. Advances in pathophysiological understanding and emerging neuroprotective interventions offer hope for more effective prevention and individualized care. Ongoing research, interdisciplinary collaboration, and adherence to evidence-based guidelines are essential for minimizing TIPN's impact and optimizing outcomes for patients undergoing cancer therapy.